Stock-Based Compensation (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 |
Nov. 06, 2022 |
Oct. 07, 2022 |
Jun. 30, 2022 |
Jun. 17, 2022 |
Jun. 30, 2021 |
May 11, 2021 |
Apr. 09, 2021 |
Aug. 12, 2020 |
Aug. 01, 2020 |
Jul. 15, 2020 |
Jul. 14, 2020 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Jun. 06, 2023 |
Mar. 31, 2023 |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Shares outstanding | 428,229 | 428,229 | 428,229 | 389,479 | |||||||||||||||||
| Stock option vested exercisable term | 21 months | ||||||||||||||||||||
| Stock based compensation | $ 280,060 | $ 424,094 | $ 557,040 | $ 763,766 | |||||||||||||||||
| Number of fully vested option exercisable | 301,979 | 301,979 | 301,979 | 281,979 | |||||||||||||||||
| Share based compensation vesting rights, percentage | 12.50% | ||||||||||||||||||||
| Total deferred compensation expense for outstanding value of unvested stock options | $ 517,000 | ||||||||||||||||||||
| Intrinsic value of exercisable but unexercised in-the-money stock options | $ 7,500 | $ 7,500 | $ 7,500 | ||||||||||||||||||
| Fair market value, per share | $ 5.88 | ||||||||||||||||||||
| Outstanding stock options to acquire shares of common stock not vested | 126,250 | ||||||||||||||||||||
| Common Stock [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock price per share | $ 57.00 | $ 57.00 | 57.00 | ||||||||||||||||||
| Director [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total of 50,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $316,700 ($6.334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $23,655 and $0, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $47,049 and $0, respectively, with respect to these stock options. | ||||||||||||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||||||||||||
| Fair value of stock options | $ 10,000 | ||||||||||||||||||||
| Stock price per share | $ 5.88 | $ 20.00 | $ 50,000 | $ 6.334 | $ 50,000 | $ 6.334 | $ 5.88 | $ 50,000 | $ 5.88 | $ 50,000 | |||||||||||
| Stock based compensation | $ 47,049 | $ 0 | |||||||||||||||||||
| Stock options are exercisable price per share | $ 5.025 | ||||||||||||||||||||
| Number of fully vested option exercisable | 10,000 | 10,000 | 10,000 | 10,000 | |||||||||||||||||
| Director [Member] | Common Stock [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Number of fully vested option exercisable | 20,000 | ||||||||||||||||||||
| Five Non Officer Directors [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total of 50,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $30.30 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($28.423 per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $106,290 and $177,150, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $211,412 and $352,355, respectively, with respect to these stock options | ||||||||||||||||||||
| Fair value of stock options | $ 43,264 | $ 316,700 | $ 1,421,095 | ||||||||||||||||||
| Stock price per share | $ 4.326 | $ 28.423 | $ 28.423 | ||||||||||||||||||
| Stock based compensation | $ 106,290 | $ 177,150 | $ 211,412 | $ 352,355 | |||||||||||||||||
| Stock options are exercisable price per share | $ 30.30 | $ 30.30 | |||||||||||||||||||
| Number of fully vested option exercisable | 10,000 | 10,000 | |||||||||||||||||||
| Non Officer Directors [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Number of fully vested option exercisable | 50,000 | 50,000 | |||||||||||||||||||
| BasvanderBaan [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Baan was granted stock options to purchase 25,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share), of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June 17, 2022 through June 30, 2024. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $9,695 and $80,647, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $19,284 and $80,647, respectively, with respect to these stock options. | ||||||||||||||||||||
| Fair value of stock options | $ 158,525 | ||||||||||||||||||||
| Stock price per share | $ 6.341 | ||||||||||||||||||||
| Stock based compensation | 9,695 | 80,647 | 19,284 | 80,647 | |||||||||||||||||
| Stock options are exercisable price per share | $ 7.40 | ||||||||||||||||||||
| Number of fully vested option exercisable | 25,000 | ||||||||||||||||||||
| Stock options granted to purchase common stock, issued | $ 79,263 | ||||||||||||||||||||
| Four Officers [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Fair value of stock options | $ 262,560 | ||||||||||||||||||||
| Stock price per share | $ 3.282 | ||||||||||||||||||||
| Stock based compensation | $ 16,352 | $ 32,524 | |||||||||||||||||||
| Number of fully vested option exercisable | 80,000 | 40,000 | |||||||||||||||||||
| Share based compensation vesting rights, percentage | 25.00% | ||||||||||||||||||||
| Share based compensation issuance, percentage | 25.00% | ||||||||||||||||||||
| Stock options granted to purchase common stock, issued | 80,000 | ||||||||||||||||||||
| Four Non Officers[Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Fair value of stock options | $ 192,593 | ||||||||||||||||||||
| Stock price per share | $ 4.8131 | $ 4.8131 | $ 4.8131 | ||||||||||||||||||
| Share based compensation vesting rights, percentage | 12.50% | ||||||||||||||||||||
| Eric J. Forman [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options granted to purchase common stock, issued | 5,833 | ||||||||||||||||||||
| Stock options description | On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted stock options to purchase 5,833 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,985 and $24,985, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $49,695 and $49,695, respectively, with respect to these stock options | ||||||||||||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||||||||||||
| Fair value of stock options | $ 400,855 | ||||||||||||||||||||
| Stock price per share | $ 68.718 | ||||||||||||||||||||
| Stock options fully vested amount, fair value | $ 100,214 | ||||||||||||||||||||
| Stock based compensation | $ 24,985 | 24,985 | $ 49,695 | 49,695 | |||||||||||||||||
| Dr. James Miser [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options granted to purchase common stock, issued | 8,333 | ||||||||||||||||||||
| Stock options description | Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase 8,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($68.718 per share), of which $143,163 was attributable to the portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $35,693 and $35,693, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $70,993 and $70,993, respectively, with respect to these stock options | ||||||||||||||||||||
| Fair value of stock options | $ 572,650 | ||||||||||||||||||||
| Stock price per share | $ 68.718 | ||||||||||||||||||||
| Stock options fully vested amount, fair value | $ 143,163 | ||||||||||||||||||||
| Stock based compensation | 35,693 | 35,693 | 70,993 | 70,993 | |||||||||||||||||
| Stock options are exercisable price per share | $ 71.40 | ||||||||||||||||||||
| Robert N. Weingarten [Member] | Employment Agreement [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase 5,833 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,985 and $24,985, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $49,695 and $49,695, respectively, with respect to these stock options | ||||||||||||||||||||
| Fair value of stock options | $ 400,855 | ||||||||||||||||||||
| Stock price per share | $ 68.718 | ||||||||||||||||||||
| Stock options fully vested amount, fair value | $ 100,214 | ||||||||||||||||||||
| Stock based compensation | 24,985 | 24,985 | 49,695 | 49,695 | |||||||||||||||||
| Stock options are exercisable price per share | $ 71.40 | ||||||||||||||||||||
| Mr Schwartberg [Member] | Director [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | On April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 25,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $32.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $753,611 ($30.144 per share), of which $376,800 was attributable to the portion of the stock options fully vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated on October 30, 2022, the date that Mr. Schwartzberg died. During the three months and six months ended June 30, 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $42,228 and $83,992, respectively, with respect to these stock options | ||||||||||||||||||||
| Fair value of stock options | $ 753,611 | ||||||||||||||||||||
| Stock price per share | $ 30.144 | ||||||||||||||||||||
| Stock options fully vested amount, fair value | $ 376,800 | ||||||||||||||||||||
| Stock based compensation | 42,228 | 83,992 | |||||||||||||||||||
| Stock options are exercisable price per share | $ 32.00 | ||||||||||||||||||||
| Number of fully vested option exercisable | 25,000 | ||||||||||||||||||||
| Ms.Regina Brown [Member] | Director [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Stock options description | the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted stock options to purchase 25,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($26.335 per share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. During the three months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $38,405 and $38,405, respectively, with respect to these stock options. During the six months ended June 30, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $76,388 and $76,388, respectively, with respect to these stock options. | ||||||||||||||||||||
| Fair value of stock options | $ 658,363 | ||||||||||||||||||||
| Stock price per share | $ 26.335 | ||||||||||||||||||||
| Stock options fully vested amount, fair value | $ 329,188 | ||||||||||||||||||||
| Stock based compensation | $ 38,405 | $ 38,405 | $ 76,388 | $ 76,388 | |||||||||||||||||
| Stock options are exercisable price per share | $ 28.00 | ||||||||||||||||||||
| Number of fully vested option exercisable | 25,000 | ||||||||||||||||||||
| 2020 Stock Incentive Plan [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Common shares avaliable for issuable | 180,000 | ||||||||||||||||||||
| Stock options granted to purchase common stock, issued | 413,333 | ||||||||||||||||||||
| Shares outstanding | 300,313 | 300,313 | 300,313 | ||||||||||||||||||
| Shares were available for issuance | 113,020 | 113,020 | 113,020 | ||||||||||||||||||
| 2020 Stock Incentive Plan [Member] | Maximum [Member] | |||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||||||||||||
| Number of restricted stock issued | 233,333 | ||||||||||||||||||||